Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma - XueYin Xu; Lian Tang; XiangHua Piao; ShaoQing Zhan; Yong Chen; PanFeng Feng (PLoS ONE, 2026)